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Background/aim: The predictability of clinical outcomes in hypertension in specific patient groups, especially underrepresented
populations is the key to rational treatment. This study aimed to investigate the impact of baseline characteristics of <65-year-old
hypertensive women with an increased risk of cardiovascular events, managed with standard- or intensive-approach, on their clinical
outcomes and serious adverse events (SAEs).
Materials and methods: Baseline characteristics of <65-year-old hypertensive women (n = 1247) in SPRINT, a multicenter randomized
trial to compare standard and intensive antihypertensive treatment, were analyzed with Cox-regression method to determine potential
predictors of the clinical outcomes and SAEs. The primary outcome was the composite of myocardial infarction (MI), non-MI acute
coronary syndrome, stroke, heart failure, or cardiovascular death.
Results: The primary outcome occurred in 3.1% and SAEs in 27.6% of the population. The treatment groups were similar in terms of
the primary outcome, SAEs, or their individual components. The primary outcome occurred significantly more in current smokers vs.
nonsmokers (HR: 2.85, 95% CI: 1.34–6.09). The subjects who were on aspirin in the intensive-group were significantly more likely to
develop the primary outcome (HR: 3.17, 95% CI: 1.23-8.19) and MI (HR: 10.15, 95% CI: 1.19-86.88) compared with those not using
aspirin. The risk of overall SAEs was significantly higher in blacks vs. nonblacks (HR: 1.27, 95% CI: 1.01-1.58), in current-smokers vs.
nonsmokers (HR: 1.59, 95% CI: 1.23-2.05), and those with vs. without chronic kidney disease (CKD), (HR: 1.38, 95% CI: 1.08-1.77). The
likelihood of SAEs significantly increased with age (HR: 1.04, 95% CI: 1.01-1.07).
Conclusion: Smoking, aspirin, CKD, black race, and age seemed as important baseline characteristics in follow-up of <65-year-old
hypertensive women, also depending on therapeutic strategy. Clinicians are expected to consider these critical parameters for effective
antihypertensive management that promotes better outcomes in this middle-aged female population.
Key words: Hypertension, middle-aged women, intensive pharmacotherapy, cardiovascular, events

1. Introduction
Sex-related variations exist in cardiovascular (CV)
anatomy and physiology, predisposing women and men
at differential CV risks [1,2]. Being more vulnerable,
hypertensive women have poorer CV outcomes than do
men, especially in the presence of CV risk factors [3–5],
despite the higher rates of awareness, antihypertensive
prescription, controlled disease, and drug compliance
among women [3,6]. Moreover, the observed sex-related
differences in CV outcome was reported to be independent
from the response to antihypertensive medications [7].
Aging further contributes to sex-related differences in
developing CV disease and outcomes [8]. In fact, female
predominance in hypertension takes place after the age of
65 years [6]. This is accompanied by less-controlled and

more severe disease in elderly hypertensive women than
their younger counterparts [9]. Hypertensive patients
usually have a number of CV disease risk factors, either
modifiable or relatively fixed. Targeting modifiable risk
factors, total CV risk assessment contributes both to
improved blood pressure (BP) control and reduced CV
disease burden [10,11]. There is substantial evidence from
clinical studies, where these risk factors are addressed
by pre-determination of specific subgroups, helping
physicians to achieve rational management of diseases
in various patient subsets. Indeed, while it might not be
possible to cover all clinical scenarios in a hypertension trial;
underrepresentation of key demographic patient strata, like
age or sex, is likely to have an impact on the generalization
of the study results, e.g. predictability of clinical outcomes
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in such populations [12–14]. Representation of women
in study populations was reported to vary from 35.2% to
59% in key hypertension trials among which the lowest rate
belonged to the recent Systolic Blood Pressure Intervention
Trial (SPRINT) [9]. In brief, SPRINT was a multicenter (n
= 102) randomized clinical trial where 9,361 hypertensive
patients at increased CV risk were assigned to either receive
standard- (a target systolic BP [SBP] of <140 mmHg) or
intensive-treatment (a target SBP of <120 mmHg) [15]. A
recent review discussed low enrollment and fewer adverse
event rates in SPRINT, implying gaps of evidence about
optimal management of hypertension in women [5]. This
might be more pronounced in younger women where the
absolute CV risk could be regarded as low. Nevertheless,
this population could also have relatively increased risk
if markedly abnormal CV risk factors are present [11]. A
better understanding of the key characteristics of such
underrepresented populations could help to predict clinical
outcomes in hypertension, and hence, contribute to the
rational management of the disease. This study aimed
to investigate the impact of baseline characteristics of
<65-year-old hypertensive women, managed with standard
or intensive approach, on their clinical outcomes and
serious adverse events (SAEs) in SPRINT.
2. Materials and methods
2.1. Study population
The rationale and design of the study and eligibility of
patients with their baseline characteristics in SPRINT
was previously described [16]. Patients were regarded at
increased CV risk if they had one or more of the following:
history of clinical or subclinical CV disease, chronic kidney
disease (CKD), 10-year Framingham risk score of ≥15%, or
age ≥75 years. Subjects were excluded if they had diabetes
mellitus, history of stroke, polycystic kidney disease,
symptomatic heart failure or reduced ejection fraction
<35%, estimated glomerular filtration rate (eGFR) <20 mL/
min/1.73 m2 or end-stage renal disease, or were (or planned
to be) pregnant [15]. In this subanalysis of the trial, we
evaluated data of female population aged below 65 years old
(range: 48–64 years).
2.2. Clinical outcomes
The primary outcome of the SPRINT was the first occurrence
of the composite of myocardial infarction (MI), non-MI
acute coronary syndrome (ACS), stroke, heart failure,
or CV death. Secondary outcomes included individual
components of the primary composite outcome, any death,
and the composite of primary endpoint or any death. We
only included these clinical endpoints to our subanalysis,
not evaluating renal outcomes in this subpopulation.
2.3. Serious adverse events
An adverse event in the study was adjudicated to be serious
if it (i) was fatal or life-threatening, (ii) led to significant

or persistent disability or any congenital anomaly/birth
defect, (iii) caused/prolonged hospitalization, or (iv) was
judged by the investigator to pose a significant hazard
or harm to the patient, requiring preventive medical or
surgical intervention. Hypotension, bradycardia, electrolyte
abnormalities, injurious falls, syncope, acute kidney injury
or acute renal failure, or any unexpected event that the
investigator believed it to be trial-related were categorized
as SAEs if they met abovementioned decision-making
criteria. Other adverse events not labelled as serious were
not included to this subanalysis.
2.4. Study variables
The baseline characteristics that were used for predicting
clinical outcomes and SAEs included ten variables: age,
SBP, diastolic BP, race, smoking status, daily aspirin use,
body mass index (BMI), total cholesterol (TC)/high-density
lipoprotein cholesterol (HDL-C) ratio, hyperglycemia, and
CKD. Among categorical variables, race was self-reported
as black or nonblack. Smoking status was grouped as
nonsmokers, former smokers, and current smokers. BMI
groups were divided into three as under-/normoweight
(<25 kg/m2), overweight (25 to <30 kg/m2), and obese
(≥30 kg/m2). The cut-off point for TC/HDL-C ratio was
chosen as 3.5 where the values above this were reported to
be indicative of CV risk among women [17]. The patients
who had a blood glucose level of ≥100 mg/dL at baseline
were categorized as hyperglycemic [18]. CKD was defined
as having an eGFR of 20–60 mL/min./1.73 m2.
2.5. Statistical analysis
Study data were analyzed using SPSS version 25.0 software
package. Descriptive baseline and outcome data were
expressed as the mean (± standard deviation) or percentage of
the population. Independent t-test were used for comparing
parametric variables, and either chi-square or Fisher’s exact
test, where appropriate, for comparing categorical variables
between standard- and intensive-treatment groups. The
abovementioned baseline characteristics were entered into
the Cox proportional hazards regression with a backward
selection to determine independent predictors of defined
outcomes. The Cox regression was performed for the total
population and for each of the standard and intensivetreatment groups separately. Only those characteristics in
the last steps that were regarded as statistically significant
predictor of the given outcome in the standard- or
intensive-treatment groups, or in overall were mentioned in
the tables for concise demonstrative purposes. Hazard ratio
(HR) was calculated with a 95% confidence interval (CI).
An overall 5% type-I error level was used to infer statistical
significance.
3. Results
We identified 1247 women who were below 65 years old
representing 13.3% of overall SPRINT cohort, where the
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median duration of follow-up was 3.25 years. The baseline
characteristics of this subgroup randomized to either
standard-treatment (n = 595) or intensive-treatment (n
= 652) were similar except slightly higher percentage of
women with increased TC/HDL-C ratio in the latter (Table
1). The primary outcome event occurred in 21 (3.5%) and
18 patients (2.8%) in standard-treatment and intensivetreatment groups, respectively. On the other hand, a total
of 341 SAEs were detected; 27.6% in the standard and
27.1% in the intensive strategy. The groups did not differ
in terms of clinical or safety outcomes or their individual
components.
3.1. Clinical outcomes
The primary outcome event occurred significantly more
in current smokers vs. nonsmokers (HR: 2.85, 95% CI:
1.34–6.09). While no such effect was found in the standardtreatment group, this effect was also significantly shown in
the intensive-treatment group consistent with those of the
overall women population. The subjects who were on aspirin
at randomization in the intensive-treatment group were
significantly more likely to develop the primary outcome
(HR: 3.17, 95% CI: 1.23–8.19) and MI (HR: 10.15, 95%
CI: 1.19–86.88) compared with those who were not using
aspirin. This association was not detected in the standardtreatment group or in overall population (Table 2).

Among other individual components of the
primary outcome, non-MI ACS was found significantly
more in women with hyperglycemia than those with
normoglycemia (HR: 9.59, 95% CI: 1.05–87.59). Heart
failure occurred significantly more in the presence of
CKD in overall (HR: 6.48, 95% CI: 1.89–22.19) and in the
standard-treatment group (HR: 5.31, 95% CI: 1.19–23.75),
whereas this effect disappeared in the intensive-treatment
group. On the other hand, those patients who were older at
randomization developed less heart failure in the intensivetreatment group (HR: 0.69, 95% CI: 0.49–0.96), an effect
which was not shown in the standard-arm or overall. No
predictors of risk were detected in terms of stroke or CV
death (Table 2).
Death from any cause was found to occur significantly
more in current smokers vs. nonsmokers (HR: 6.46, 95%
CI: 1.75–23.81) and in women with vs. without CKD (HR:
3.50, 95% CI: 1.31–9.37). While similar effects were also
consistently observed in the standard-treatment group,
no such significant associations were detected in the
intensive-arm (Table 2).
Primary outcome event or death occurred significantly
more in former (HR: 2.27, 95% CI: 1.07–4.84) or current
(HR: 4.15, 95% CI: 2.13–8.08) smokers vs. nonsmokers.
The risk was also significantly higher in patients with vs.

Table 1. Baseline characteristics of the study groups.
Standard-treatment
n = 595

Intensive-treatment
n = 652

Age, y (mean ± SD)

58.4 ± 4.0

58.6 ± 3.9

Black origin, %

60.5

58.0

Under-/normoweight, %

12.7

14.2

Overweight, %

29.5

25.6

Obese, %

57.8

60.2

Systolic blood pressure, mmHg (mean ± SD)

140.1 ± 17.4

140.4 ± 17.3

Diastolic blood pressure, mmHg (mean ± SD)

83.8 ± 11.9

83.9 ± 11.4

Never, %

49.3

49.1

Former, %

23.4

22.8

Current, %

27.3

28.1

Hyperglycemia (≥100 mg/dL), %

39.5

37.4

TC/HDL-C ratio ≥3.5, %*

59.0

65.3

CKD (eGFR < 60 mL/min/1.73 m ), %

20.5

21.0

Aspirin use, %

35.8

33.5

Body mass index category

Smoking

2

*P = 0.02; CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate; TC/HDL-C: Total
cholesterol/high-density lipoprotein cholesterol.
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Table 2. Predictors of clinical outcomes by treatment groups.
Total
Clinical outcomes*

Standard-treatment

Intensive-treatment

HR (95% CI)

P-value HR (95% CI)

P-value HR (95% CI)

P-value

Current vs. no smoking

2.85 (1.34–6.09)

0.007

2.54 (0.93–6.92)

0.068

3.86 (1.16–12.84) 0.028

Aspirin vs. no aspirin use

1.61 (0.86–3.03)

0.137

0.91 (0.35–2.34)

0.852

3.17 (1.23–8.19)

1.91 (0.67–5.44)

0.227

0.59 (0.12–2.91)

0.514

10.15 (1.19–86.88) 0.034

9.59 (1.05–87.59)

0.045

n/a

0.932

n/a

0.770

0.92 (0.79–1.06)

0.246

1.02 (0.83–1.24)

0.875

0.69 (0.49–0.96)

0.026

0.029

21.31 (0.54–
841.16)

0.103

SPRINT primary outcome (n = 39)
0.017

Myocardial infarction (n = 14)
Aspirin vs. no aspirin use
Nonmyocardial infarction ACS (n = 6)
Hyperglycemia vs. normoglycemia
Heart failure (n = 11)
Age at randomization
CKD vs. no CKD
(eGFR ≥ 60 mL/min/1.73 m2)

6.48 (1.89–22.19)

0.003

5.31 (1.19–23.75)

Current smoking vs. no smoking

6.46 (1.75–23.81)

0.005

15.26 (1.79–130.15) 0.013

3.26 (0.53–19.88) 0.201

CKD vs. no CKD
(eGFR ≥ 60 mL/min/1.73 m2)

3.50 (1.31–9.37)

0.012

9.74 (2.66–35.59)

0.001

0.58 (0.07–4.91)

0.613

Death from any cause (n = 17)

SPRINT primary outcome or any death (n = 54)
Former smoking vs. no smoking

2.27 (1.07–4.84)

0.033

1.96 (0.69–5.58)

0.209

2.73 (0.92–8.12)

0.072

Current smoking vs. no smoking

4.15 (2.13–8.08)

0.000

5.00 (2.04–12.25)

0.000

3.50 (1.29–9.49)

0.014

Aspirin vs. no aspirin use

1.49 (0.87–2.54)

0.148

1.11 (0.51–2.42)

0.793

2.38 (1.06–5.31)

0.035

CKD vs. no CKD
(eGFR ≥ 60 mL/min/1.73 m2)

1.96 (1.10–3.52)

0.023

3.65 (1.75–7.61)

0.001

0.68 (0.54–2.05)

0.497

* Stroke (n = 9) and cardiovascular death (n = 2) were not included to the table as Cox regression yielded no significant predictor in any
of the treatment arms or in overall.
ACS: Acute coronary syndrome; CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate.

without CKD (HR: 1.96, 95% CI: 1.10–3.52). The subjects
who were under aspirin in the intensive-treatment group
were more likely to develop the primary outcome or death
compared with patients who were not using aspirin at
baseline (HR: 2.38, 95% CI: 1.06–5.31), (Table 2).
3.2. Serious adverse events
The risk of overall SAEs was significantly higher in those
with black vs. nonblack origin (HR: 1.27, 95% CI: 1.01–
1.58), in current smokers vs. nonsmokers (HR: 1.59, 95%
CI: 1.23–2.05), and those with vs. without CKD (HR: 1.38,
95% CI: 1.08–1.77). While these risks were also observed
in the standard-treatment group, no such association was
found in the intensive-treatment group. In addition, the
likelihood of SAE significantly increased with the age (HR:
1.04, 95% CI: 1.01–1.07), and the effect was also observed
to disappear in the intensive-treatment group (Table 3).
In terms of treatment-related SAEs, a consistently
significant effect was shown across groups for the

presence of CKD towards more events. Black vs. nonblack
women and current smokers vs. nonsmokers developed
significantly more related SAEs overall (HR: 5.44,
95% CI: 1.59–18.60 and HR: 3.55, 95% CI: 1.22–10.30;
respectively), an effect not observed in the standard- or
intensive-treatment group (Table 3).
The risk of serious hypotension was elevated in patients
with vs. without CKD (HR: 6.20, 95% CI: 2.02–19.03),
which was also observed in the standard-treatment group.
No parameter was found to predict a serious bradycardia
event in either treatment groups or overall (Table 3).
While serious syncope events developed more in
current smokers vs. nonsmokers (HR: 4.54, 95% CI:
1.17–17.57) overall; the risk was also significantly higher
in obese vs. normo/underweight women in the intensivetreatment arm (HR: 22.87, 95% CI: 2.13–245.85). On the
other hand, injurious falls occurred significantly more
in patients with vs. without CKD only in the intensive-
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Table 3. Predictors of serious adverse events by treatment groups.
Total
Serious adverse events

Standard-treatment

Intensive-treatment

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Age at randomization

1.04 (1.01–1.07)

0.012

1.06 (1.01–1.10)

0.005

1.02 (0.97–1.06)

0.475

Black vs. nonblack ethnicity

1.27 (1.01–1.58)

0.037

1.63 (1.16–2.28)

0.005

1.05 (0.77–1.43)

0.740

Current smoking vs. no smoking

1.59 (1.23–2.05)

0.000

1.81 (1.25–2.61)

0.002

1.33 (0.94–1.88)

0.105

CKD vs. no CKD
(eGFR ≥ 60 mL/min/1.73 m2)

1.38 (1.08–1.77)

0.011

1.83 (1.30–2.58)

0.001

1.06 (0.74–1.52)

0.741

Black vs. nonblack ethnicity

5.44 (1.59–18.60)

0.007

n/a

0.958

2.83 (0.78–10.20)

0.111

Current smoking vs. no smoking

3.55 (1.22–10.30)

0.020

5.18 (0.82–32.88)

0.081

2.54 (0.64–10.14)

0.186

CKD vs. no CKD
(eGFR ≥ 60 ml/min/1.73 m2)

3.76 (1.58–8.97)

0.003

6.27 (1.30–30.30)

0.022

3.47 (1.11–10.85)

0.033

6.20 (2.02–19.03)

0.001

23.19 (2.26–237.84) 0.008

3.51 (0.87–14.10)

0.077

Current smoking vs. no smoking

4.54 (1.17–17.57)

0.029

9.76 (0.92–103.95) 0.059

2.12 (0.34–13.16)

0.419

Obese vs. normo/underweight

0.31 (0.08–1.26)

0.102

n/a

0.958

22.87 (2.13–245.85)

0.010

Overweight vs. normo/underweight

0.51 (0.21–1.27)

0.148

1.14 (0.21–6.21)

0.880

0.28 (0.09–0.89)

0.031

Obese vs. normo/underweight

0.33 (0.14–0.77)

0.010

0.66 (0.11–3.85)

0.648

0.25 (0.09–0.65)

0.005

2.44 (0.77–7.76)

0.129

n/a

0.949

4.78 (1.23–18.58)

0.024

Any (n = 341)

Related (n = 22)

Hypotension (n = 13)
CKD vs. no CKD
(eGFR ≥ 60 mL/min/1.73 m2)
Syncope (n = 11)

Electrolyte abnormality (n = 34)

Injurious fall (n = 12)
CKD vs. no CKD
(eGFR ≥ 60 mL/min/1.73 m2)

Acute kidney injury or acute renal failure (n = 27)
Black vs. nonblack ethnicity

4.02 (1.51–10.74)

0.005

3.84 (0.72–20.59)

0.117

4.26 (1.20–15.18)

0.025

Former smoking vs. no smoking

3.80 (1.47–9.85)

0.006

1.41 (0.30–6.62)

0.665

11.27 (2.37–53.60)

0.002

Current smoking vs. no smoking

3.08 (1.13–8.35)

0.027

1.11 (0.19–6.48)

0.904

6.89 (1.39–34.20)

0.018

Systolic blood pressure

1.01 (0.99–1.04)

0.175

0.97 (0.91–1.03)

0.266

1.03 (1.01–1.05)

0.029

CKD vs. no CKD
(eGFR ≥ 60 mL/min/1.73 m2)

9.14 (4.05–20.63)

0.000

n/a

0.906

4.78 (1.75–13.03)

0.002

CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate.

treatment group (HR: 4.78, 95% CI: 1.23–18.58). Serious
electrolyte abnormalities developed less among overweight
or obese vs. normo/underweight women, which was
especially marked in the intensive-treatment group (HR:
0.28, 95% CI: 0.09–0.89 and HR: 0.25, 95% CI: 0.09–0.65,
respectively), (Table 3).
The risk of acute kidney injury or renal failure SAE
was significantly increased among black population (HR:
4.02, 95% CI: 1.51–10.74), in former (HR: 3.80, 95% CI:
1.47–9.85) or current smokers (HR: 3.08, 95% CI: 1.13–
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8.35), and in women with CKD (HR: 9.14, 95% CI: 4.05–
20.63); which were also shown in the intensive-treatment
arm compared to those in the standard-treatment arm.
In addition, the risk was also significantly higher with
elevated basal SBP only in the intensive-treatment group
(HR: 1.03, 95% CI: 1.01–1.05), (Table 3).
4. Discussion
This study is expected to contribute to the treatment
approach of middle-aged hypertensive women which
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seems to represent a comparably gray zone. The subanalysis
of the SPRINT in <65-year-old female population has
featured several baseline characteristics for the follow-up
of hypertension, managed with either standard or intensive
approach: smoking, aspirin use, CKD, hyperglycemia, and
the age for the risk of clinical outcomes and SAEs; black
race and BMI only for SAEs. These key characteristics
seem to be associated with several outcomes or events
distinctively, which may depend on selection of the
standard- or intensive-treatment strategy.
A well-established risk factor for CV disease [10],
smoking was reported to affect women more adversely
than men [1,19]. Furthermore, a study showed the largest
gap between smoking women and men compared to their
never-smoking counterparts in terms of increased MI risk
occurred between ages of 55–64 years [20]. Consistently,
our subgroup analysis in middle-aged women also showed
current smoking to be associated with higher risk for
the primary outcome, any death, and several SAEs (any,
related, syncope, and acute kidney injury/failure). Indeed,
though less pronounced, the risk was also partially
relevant for former smokers vs. nonsmokers, supporting
the reduced CV disease risk upon smoking cessation
[21]. On the other hand, association of active smoking
at baseline with increased CV risk was only significant in
the intensive-treatment group, suggesting a failure of the
strategies targeting SBP goal <120 mmHg among active
smoker vs. nonsmoker middle-aged hypertensive women.
In fact, a recent analysis of SPRINT and ACCORD data
reported current smokers to benefit less from the intensive
treatment [22].
In overall study population, aspirin use at
randomization was not associated with the primary
outcome. Recently, three consecutive studies have
reported that aspirin treatment had only limited and
costly preventive effect, if any, in patients with increased
CV risks [23–25]. Among these studies, ARRIVE study
involved patients comparable to our population, reporting
no significant benefit of aspirin in nondiabetic, >60-yearold cases with no interaction by age or sex [23]. Therefore,
it may be suggested that aspirin treatment in <65-yearold women, a comparably lower risk group indeed [26],
would not be expected to have a substantial preventive
effect. On the other hand, the significantly higher risk of
the primary outcome and MI among aspirin users in the
intensive-treatment arm could have clinical importance.
The presence of such an aspirin-based risk gap merely
in this group implies that the decision towards intensive
treatment in middle-aged hypertensive women should
be reevaluated in case that they receive aspirin for a
particular indication. Though we did not have data about
the purpose of aspirin therapy -primary or secondary-, its
concomitance with intensive BP-lowering strategy appears

to worsen the outcomes, while it merits further research to
elucidate underlying mechanisms or contributing factors.
Not just an independent risk factor for CV disease,
CKD further seems to compel benefit/risk ratio of BPlowering therapy in terms of target goals [27]. We observed
a positive association of CKD to the increased risk of
heart failure near 6.5-fold, and to lesser but significantly
raised risks of total mortality, composite endpoints, and
several SAEs in this middle-aged hypertensive women
population. While this pattern was mainly preserved in
the standard-treatment group, CKD in the intensivetreatment group was not associated with increased risk of
clinical or safety outcomes, except treatment-related and
acute kidney injury/failure SAEs. The difference in favor
of intensive strategy is consistent with meta-analyses and
CKD subanalysis of the SPRINT [28,29], confirming the
benefits of such approach also in middle-aged hypertensive
women with CKD. Furthermore, a recent subanalysis
reported that most of such acute kidney injury events
are mild in nature and completely resolved [30], which
may help to relieve such potential concerns. It might be
suggested that intensive approach could be encouraged in
this patient subgroup accompanying CKD.
The incidence of hypertension and its associated
mortality is higher in blacks vs. whites [6]. Indeed, African
American postmenopausal women in Women’s Health
Initiative study were reported to have lowest rate of ideal CV
health [31]. While black race was associated with greater
CV benefit of intensive treatment in the SPRINT overall
[22], it did not predict clinical outcomes in our subanalysis
of middle-aged women. By contrast, being a <65-year-old
hypertensive black women was associated with increased
risks of any, related, and acute kidney injury/failure SAEs
in our study. Especially the latter may be attributed to the
underlying etiology of racial disparities in hypertension,
involving reduced ability to excrete sodium loading and
different renin-angiotensin-aldosterone system in blacks
[32]. In addition, >50-year-old black women were reported
to be far more beyond their recommended threshold level
of sodium intake than were their white counterparts
despite similar amount of consumption [33]. Whether this
may contribute to increased SAEs among black women
warrants further research.
Age was associated with a lower risk of heart failure
in the intensive-treatment group. On the contrary, a study
on young adult heart failure patients reported similar
rates of underlying hypertension and comparable use of
antihypertensive drugs between 50–59- and 60–69-years’
age groups, suggesting no age-related association [34].
This is likely to indicate the benefit of selecting intensive
antihypertensive strategy to prevent heart failure in
middle-aged women as their age increases. It is further
enhanced by the absence of increased risk of any SAEs

1303

AYDIN et al. / Turk J Med Sci
in the intensive-treatment group, unlike the standardtreatment group. While older age is expected to be
correlated with higher SAE rates [35,36], no association
of age to the treatment-related SAEs may help to attenuate
potential age-based SAE concerns, if any, in <65-year-old
hypertensive women population.
Despite being a well-known risk factor for hypertension
[37], obesity did not predict clinical outcomes in <65-yearold hypertensive women in this study. By contrast,
it appeared to be negatively associated with serious
electrolyte abnormalities and positively associated with
syncope particularly in the intensive-treatment group.
The latter could be partly attributed to the potent reversal
of increased sympathetic nervous system activity, an
important mechanism of hypertension in obese patients
[38]. Whatever the reason, it may be advised for physicians
managing obese hypertensive women to pay more
attention in accurate BP measurement when considering
intensive strategy. This is based on the fact that erroneous
measurements due to mismatched cuff size in obese people,
still a common practice, lead to overestimated readings and
consequently unnecessary treatment [39]. This, in turn,
may translate into overshooting of <120 mmHg target,
aggravating already raised syncope risk. On the other
hand, decreased risk of serious electrolyte abnormalities
could be related with expanded intravascular volume
among obese hypertensive patients [40] and elevated
plasma solute concentrations in obese people [41]. This
may imply a higher tolerability to clinically relevant
electrolyte imbalances by antihypertensive medication.
Considering the CV disease burden caused by obesity, it
may be suggested that its relative protective role against
electrolyte abnormalities not be overemphasized.
The positive association of baseline hyperglycemia
with non-MI ACS regardless of antihypertensive
strategy should be evaluated in caution. While a recent
study reported higher CV or coronary mortality in ever
prediabetic patients than normoglycemic patients [42],
the lack of such impact of hyperglycemia on other clinical
outcomes, i.e. being confined to unstable angina mostly,
seem to call the finding in question. In addition, any
deterioration in glycemic status during the study might
have a confounding effect.
More patients with high TC/HDL-C ratio existed in
the intensive-arm at baseline, yet this did not reflect as
difference in clinical outcomes. Potentially influenced by
several factors such as dietary habits, physical exercise,
or lipid-lowering drugs [43], TC/HDL-C ratio does not
appear as a good predictor to determine either standard
or intensive therapy in middle-aged hypertensive women.
Polypharmacy is well-recognized risk factor for adverse
effects [44]. This, at first sight, imply increased risk of
adverse effects in the intensive group. However, SAE rates
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did not differ between treatment arms, suggesting that it
is advisable not to overvalue the role of SAEs in selecting
antihypertensive strategy in favor of or against to intensive
therapy.
Our subanalysis has several limitations. First, in this
middle-aged women population, a 3.25-year median
follow-up could be regarded as a comparably shorter
period to disclose the differences between treatment
arms in terms of clinical outcomes. This might also reflect
into the predictability of examined variables, as evident
by broad CIs in several outcomes where fewer events
occurred. Second, rather than being based on individual
and single measurements, BP assessments were made with
respect to the intended SBP target of the SPRINT, <140
or <120 mmHg. In addition, study design did not force
participating clinicians in favor of any antihypertensive
class or dose as long as they were guideline-based.
Therefore, individual BP recordings and antihypertensive
medications and their doses might influence the impact
of some risk factors at individual basis. However, it could
be suggested that this effect is unlikely to be that much
pronounced as the study design applied for both of the
treatment arms. Third, there was no baseline data about
the use of hormone replacement therapy (HRT) in this
subgroup. Though evidence showed that HRT resulted
only small BP changes [45,46]; there is possibility that
HRT could interact with particular antihypertensive
medications that might influence future outcomes. On the
other hand, menopausal transition was reported not to
substantially act on CV outcomes [8]. In fact, the risk was
suggested to depend on patients’ lifestyles rather than their
hormone profile [47]. Finally, it is important to note that,
the examined variables were recorded at the beginning
of the study as baseline characteristics and the possible
changes during the follow-up period were not evaluated.
In conclusion, smoking, aspirin use, CKD,
hyperglycemia, black race, age, and BMI seemed as
important baseline characteristics in the follow-up of
<65-year-old hypertensive women, also depending on
the therapeutic strategy. Consistent with total CV risk
assessment concept, the success of antihypertensive
treatment in daily practice –not confined to only BP
values- is enhanced by on-point and rational consideration
of suitable baseline parameters of patient subsets. This is
especially relevant for populations underrepresented in
trials, where subgroup analyses like the current one, aim to
shed light on. In this context, such subanalyses could help
to customize identify and measure the impact of associated
baseline factors in particular patient populations.
Therefore, abovementioned baseline parameters should be
considered for a rational antihypertensive management,
including treatment and follow-up, that contributes to
prevent CV outcomes and avoid SAEs in this middle-
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aged female population with increased CV risk. With a
higher life expectancy in the real-world setting, middleaged hypertensive women might have better outcomes
if intensity of BP-lowering strategy is built on predictive
factors at baseline.
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